Integrum AB (INTEG B) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

The company has declared Negative results for the last 3 consecutive quarters

PRE-TAX PROFIT(Q) At SEK -11.86 MM has Fallen at -68.02%
NET PROFIT(Q) At SEK -9 MM has Fallen at -84.11%
OPERATING CASH FLOW(Y) Lowest at SEK -37.7 MM

Risky -

Below par performance in long term as well as near term

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

SEK 178 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.15

Return on Equity

-18.68%

Price to Book

1.06

Revenue and Profits:

Net Sales:

24 Million

(Quarterly Results - Jul 2025)

Net Profit:

-10 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-75.06%

6 Months

-50.82%

1 Year

-48.67%

2 Years

-73.57%

3 Years

-71.42%

4 Years

-81.05%

5 Years

-64.75%

Integrum AB for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

26.32%

EBIT Growth (5y)

-210.60%

EBIT to Interest (avg)

-13.75

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.21

Sales to Capital Employed (avg)

0.58

Tax Ratio

27.44%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

0.11%

ROE (avg)

3.24%

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.49

EV to EBIT

-5.23

EV to EBITDA

-6.19

EV to Capital Employed

1.58

EV to Sales

2.33

PEG Ratio

Dividend Yield

ROCE (Latest)

-30.16%

ROE (Latest)

-18.68%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

Bullish

No Signal

Bollinger Bands

Mildly Bearish

Moving Averages

Mildly Bearish (Daily)

KST

Bearish

Dow Theory

Mildly Bullish

Mildly Bearish

OBV

Mildly Bullish

Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot

No data for shareholding present.

Shareholding Compare (%holding)

No data for shareholding present.

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jul'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jul 2025 is -12.18% vs 14.35% in Apr 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jul 2025 is -11.11% vs -157.14% in Apr 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'25",
        "Apr'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "23.80",
          "val2": "27.10",
          "chgp": "-12.18%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-10.40",
          "val2": "-8.10",
          "chgp": "-28.40%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.00",
          "val2": "-9.00",
          "chgp": "-11.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-508.60%",
          "val2": "-361.00%",
          "chgp": "-14.76%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Apr'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Apr 2025 is -12.49% vs 40.11% in Apr 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Apr 2025 is -870.00% vs 124.69% in Apr 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Apr'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "91.10",
          "val2": "104.10",
          "chgp": "-12.49%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-35.00",
          "val2": "2.90",
          "chgp": "-1,306.90%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.50",
          "val2": "0.60",
          "chgp": "-16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-30.80",
          "val2": "4.00",
          "chgp": "-870.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-456.10%",
          "val2": "6.60%",
          "chgp": "-46.27%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jul'25 - QoQ

Jul'25

Apr'25

Change(%)

Net Sales

23.80

27.10

-12.18%

Operating Profit (PBDIT) excl Other Income

-10.40

-8.10

-28.40%

Interest

0.10

0.20

-50.00%

Exceptional Items

0.00

Consolidate Net Profit

-10.00

-9.00

-11.11%

Operating Profit Margin (Excl OI)

-508.60%

-361.00%

-14.76%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jul 2025 is -12.18% vs 14.35% in Apr 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jul 2025 is -11.11% vs -157.14% in Apr 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Apr'25

Apr'25

Apr'24

Change(%)

Net Sales

91.10

104.10

-12.49%

Operating Profit (PBDIT) excl Other Income

-35.00

2.90

-1,306.90%

Interest

0.50

0.60

-16.67%

Exceptional Items

0.00

Consolidate Net Profit

-30.80

4.00

-870.00%

Operating Profit Margin (Excl OI)

-456.10%

6.60%

-46.27%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Apr 2025 is -12.49% vs 40.11% in Apr 2024

Consolidated Net Profit

YoY Growth in year ended Apr 2025 is -870.00% vs 124.69% in Apr 2024

All Annual Results

Company CV

About Integrum AB

Integrum AB

Pharmaceuticals & Biotechnology

Integrum AB is a Sweden-based company within healthcare sector. It provides systems for bone-anchored prostheses for individuals with amputations. The Company’s solutions comprise OPRA Implant System, neural prosthetics, phantom limb pain treatment and prosthetic components. The OPRA implant system is based on osseointegration, enabling the direct connection of an artificial limb to the skeleton. The neural prosthetics technology implies ability to directly connect bionic prostheses to the patient’s bone, nerves, and muscles. A method for limb pain treatment implies motor execution of the phantom limb as a treatment, which is aided by machine learning, augmented and virtual reality. The Company provides a variety of prosthetic components required to connect the OPRA Implant System to external prostheses.

Company Coordinates

Company Details

Krokslatts Fabriker 50 , MOLNDAL None : 431 37

Tel: 46 31 7601060

http://integrum.se/

Registrar Details